RxDoctor Payments Data

Joseph Goin, MD

General Practice · Cleveland, TXNPI 1730189408

Payments from drug & device makers

$5,644in general payments, 2019–2025

Across 282 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$898
  • Tris Pharma Inc$791
  • Supernus Pharmaceuticals, Inc.$595
  • AbbVie$416
  • Mylan Specialty L.p.$203
  • Pfizer$187
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,58699%
  • Education$581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,644 in reported general payments places this provider in the 95th percentile of 8,074 general practice providers in Texas.

See all general practice providers in Texas

Medicare billing

Part B allowed, 2024
$228,089
Medicare patients
431
Services billed
6,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$117,637
OzempicSemaglutide92$98,879
Trelegy ElliptaFluticasone/Umeclidin/Vilanter113$96,382
JardianceEmpagliflozin97$91,346
RinvoqUpadacitinib13$87,099
EliquisApixaban75$70,601
TrulicityDulaglutide52$65,063
FarxigaDapagliflozin Propanediol54$48,134
GemtesaVibegron42$32,026
JanuviaSitagliptin Phosphate26$28,297
XareltoRivaroxaban19$20,053
RexultiBrexpiprazole13$19,433
Combivent RespimatIpratropium/Albuterol Sulfate24$15,878
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$15,329
LinzessLinaclotide24$14,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$96$182,700148 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$898$115,777180 claims
AbbVieRinvoq, Linzess$416$101,96037 claims
Novo NordiskOzempic$89$98,87992 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$135$75,29099 claims
PfizerEliquis$187$70,60175 claims
MerckJanuvia, Janumet$111$36,76640 claims
Sumitomo Pharma America, Inc.Gemtesa$30$32,02642 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$19,43313 claims
Astellas Pharma US IncMyrbetriq$47$6,69213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,074 general practice providers in Texas.

Other general practice in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →